Healthcare Professional Man in suit

Your Partnership Matters in Cancer Research

We are passionate about improving health and are committed to helping people with cancer. The purpose of the Keynote Oncology Clinical Trials is to determine whether the investigational immunotherapy, pembrolizumab (MK-3475), may help in the treatment of cancer. We have clinical trials planned in multiple cancer types.

Pembrolizumab is a PD-1 blocking antibody that may block the interaction between the programmed cell death-1 receptor (PD-1) and its ligands, PD-L1 and PD-L2. In some patients, blocking this pathway may enable the immune system to fight the cancer.

Pembrolizumab has been FDA-approved for use in certain types of cancer.

There is a great deal more to understand and learn about which patients are likely to respond to immunotherapy. Ongoing research may help us understand this, as well as provide insights regarding how to best test for expression of biomarkers that may better direct clinical care.

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

57

Trials in 30+ cancer types

Explore Active Clinical Trials

  • expand all
  • |
  • collapse all
Trial Description Keynote Trial Condition Phase Status
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer 407 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer 189 Non-Small-Cell Lung Carcinoma Phase 3 Active, not recruiting
Study of Pembrolizumab in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma 001 Cancer, Solid Tumor Phase 1 Active, not recruiting
Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer 010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Active, not recruiting
Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer 011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1 Recruiting
Study of Pembrolizumab in Participants With Advanced Non-small Cell Lung Cancer 025 Non-small Cell Lung Cancer Phase 1 Completed
A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer 021 Non-small Cell Lung Carcinoma Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer 024 Non-Small Cell Lung Carcinoma Phase 3 Active, not recruiting
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer 032 Non-Small-Cell Lung Cancer Phase 1 Active, not recruiting
Study of MK-3475 Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer 042 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy 091 Non-small Cell Lung Cancer Phase 3 Recruiting